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CHAPTER I 
INTRODUCTION 
Increasing the incidence of multiple births in beef cattle could 
markedly improve the reproductive efficiency of cow herds, and calf 
crops of over 100% could be obtained. The mechanism for doing this has 
been demonstrated. Numerous researchers have reported that the injec-
tion of pregnant mare serum gonadotrophin (PMSG) will induce superovu-
lation and superfetation in cows. However, from a practical standpoint 
there are several problems limiting the use of this technique. 
One of the most important of these problems is the tremendous amount 
of labor required to carry out the treatment.s. The occurrence of estrus 
must be accurately detected to permit rather precise timing of the hor-
mone injections. In addition, because of the variation in time of the 
occurrence of estrus in a herd of cows, the gonadotrophins must be ad-
ministered on an individual cow basis. 
Another problem associated with the induction of multiple births 
by gonadotrophin injections is the large variation in the number of 
ovulations in a group of animals all of which were given the same quant-
ity of hormone. The reasons for this variation have never been deter-
mined with certainty. One possibility is that it may be related to the 
variation in the interval of time between the PMSG injection and estrus. 
Several studies have shown that ~s this interval increased, the number 
of follicles also increased. Reducing the variation in the interval 
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from PMSG to estrus might also reduce the variation in ovulatory re-
sponse. The variation in response may also be related to the timing of 
PMSG injections since it has been reported that a series of two injec-
tions, one in the early luteal phase and the other in the late luteal 
phase of the estrous cycle, tends to reduce the number of excessive 
ovulations. 
In recent years, research with a group of naturally occurring com-
pounds called prostaglandins has suggested a possible means of reducing 
the labor requirement and controlling the ovulation rate. A single 
intramuscular injection of prostaglandin F2a into cows with a functional 
corpus luteum will result in at least 80% of the cows exhibiting estrus 
in the period two to four days following the injection. With this sue-
cessful synchronization of estrus, it may be possible to give gonadotro-
phin injections to cause multiple ovulations at a set interval after 
synchronization. If all of the cows could be treated on the same day, 
the labor requirement could be greatly reduced. 
In addition, PGF2 has been shown to cause rapid regression of the a . 
corpus luteum as evidenced by a rapid decline in plasma progesterone 
after treatment. Therefore, if PGF2a was given one day after PMSG, it 
might reduce the number of ovulations by decreasing the interval from 
PMSG to estrus. 
The object of this study was: (1) to determine the superovulatory 
response of cows to PMSG injections timed from an estrus induced by in-
jecting PGF2a; (2) to attempt to control the number of ovulations by 
reducing the time interval from PMSG to estrus by injecting prostaglan-
din F2a following the PMSG injection; (3) to determine the superovulatory 
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response of cows to PMSG and prostaglandin F2a given in mid cycle and 
in late cycle; (4) to determine the blood plasma concentrations of pro-
gesterone and estradiol associated with the above treatments. 
CHAPTER II 
LITERATURE REVIEW 
Plasma Concentrations of Ovarian Hormones During 
The Bovine Estrous Cycle 
The concentrations of progesterone and estradiol in peripheral 
blood plasma follows a regular pattern through the four periods of the 
estrous cycle of the bovine: proestrus, estrus, metestrus and diestrus. 
Proestrus, the period just preceeding estrus, generally lasts two to 
three days (McDonald, 1971). It is during this time that the ovarian 
follicles are growing rapidly and the production of estradjol reaches a 
maximum. Wettemann et al. (1972), Glencross et al. (1973) and Chenault 
et al. (1975) reported that the plasma concentration of estradiol in-
creases from basal levels of 2-3 pg/ml to a maximum of 6-9 pg/ml. In 
contrast, Dobson et al. (1973) reported basal levels of estradiol to be 
5 pg/ml and a maximum peak of 14 pg/ml. The plasma progesterone concen-
tration decreases rapidly as proestrus advances and declines to about 
1 ng/ml or less. 
Following proestrus is the period of sexual receptivity, estrus, 
which lasts approximately 14-18 hours in the cow (McDonald, 1971). 
Estrus is characterized by high levels of plasma estradiol (6-9 pg/ml), 
which decline as estrus advances, and a very low plasma progesterone 
concentration. Plasma progesterone levels during estrus vary between 
4 
0 and 1 ng/ml (Kazana and Hansel, 1970; Stabenfeldt et al., 1969; 
Wettemann et al., 1972; Chenault et al., 1972 and Lemon et al., 1975). 
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Metestrus, the period following estrus, is characterized by the 
ovulation of the ripened follicle 12-15 hours after the cessation of 
estrus (McDonald, 1971). During the first day of metestrus, circulating 
levels of estradiol return to their basal levels of 2-3 pg/ml and the 
formation of the corpus luteum begins (Chenault et al., 1975). Plasma 
progesterone concentrations remain low through most of the 2-3 days of 
metestrus, reaching their lowest levels approximately twenty hours after 
the detection of estrus (Sprague et al., 1971). The plasma progesterone 
concentration begins to increase as the period of diestrus approaches. 
Diestrus is by far the longest period of the bovine estrous cycle, 
lasting approximately 15 days (McDonald, 1971). It is during this time 
that the corpus luteum develops into a functional body secreting large 
amounts of progesterone. Plasma progesterone concentrations increase 
rapidly during the first 5-6 days of diestrus with a more gradual in-
crease to maximum concentrations late in this stage (Stabenfeldt et al., 
1969). Plasma progesterone increases from 0-1 ng/ml during estrus to 
6-10 ng/ml at its maximum in late diestrus, approximately 4-6 days 
before the next estrus (Stabenfeldt et al., 1969; Wettemann et al., 1Q72 
and Glencross et al., 1973). During most of diestrus, plasma estradiol 
remains at basal concerntrations, although some studies have detected 
increased plasma estrogen for short durations of this period (Glencross 
et al., 1973; Lemon et al., 1975). During the final few days of dies-
trus, the concentration of plasma progesterone begins to decrease while 
plasma estradiol concentrations begin to increase to those observed 
during proestrus. 
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Ovarian Response of the Bovine Treated with 
PMSG 
Pregnant mare serum gonadotrophin (PMSG) has been shown to cause 
superovulation in cows and heifers both before and after puberty. 
Siedel et al. (1971) demonstrated that prepuberal heifers as young as 
one month of age could be stimulated to produce large numbers of folli-
cles when given PMSG. Calves of O, 1, and 2 months of age which were 
injected with 1500 I.U. PMSG, followed five days later by 50 rng. L.H., 
produced an average of 0, 9.4, and 28.2 ovulations per group, respec-
tively. Furthermore, by five months of age calves could be stimulated 
to produce an average of 77.2 ovulations when injected with 1500-2000 
I.U. PMSG and 75 mg L.H. five days later. Other research has supported 
these findings by demonstrating that 17 week old calves given various 
combinations of PMSG and L.H. or PMSG and H.C.G. produced an average of 
53 follicles greater than 1 cm in diameter (Onuma et al., 1970). 
The majority of research with PMSG, however, has been concerned 
with the postpuberal animal. In general, as the dosage of PMSG is in-
creased, the number of ovulations also increased. Gordon et al. (1962) 
reported that groups of cows given 800, 1000, 1200, 1600 or 2000 I.U. 
PMSG produced an average of 1.43, 1.77, 2.50, 2.71 and 3.97 ovulations 
per group, respectively. Rowson (1950) demonstrated that the injection 
of 3600 or 4500 I.U. PMSG produced an average of 26 follicles and he 
also reported that when 2000 I.U. chorionic gonadotrophin was injected 
intravenously after the PMSG, there was an increase in the number of 
follicles that ovulated. 
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Differences in the superovulatory response may be due to the method 
of preparation of PMSG. Rowson (1950) demonstrated that 3600 I.U. bf 
processed PMSG (purified gonadotrophin) produced an average of 13.3 fol-
licles per animal while the same dosage of whole PMSG produced 30.0 fol-
licles per animal. Another report comparing processed PMSG to fresh, 
whole PMSG and to freeze dried PMSG and obtained 13.9, 20.1 and 14.5 
follicles per group, respectively (Brock and Rowson, 1952). 
Most researchers working in this area have reported that the major 
problem with using PMSG is the tremendous variation in ovarian response 
between animals given the same dosage. Hafez et al. (1963) observed a 
range in ovulations from 7 to 62 when 3000 I.U. PMSG was given to cows 
on the sixteenth day of the cycle, followed five days later by 2000 I.U. 
HCG. He also reported ovulation rates from 6 to 52 when cows were in-
jected with 5000 I.U. PMSG in two equal doses an the sixteenth and 
seventee11th days of the cycle, plus expressing the corpus luteum and 
injecting 2000 I.U. HCG. In 1964 Hafez et al. reported a range of 2 to 
10 ovulations per cow when treated with 1500 I.U. PMSG on day 16 and a 
range of 2 to 14 ovulations when 2000 I.U. PMSG was used. These ranges 
were 2-10 and 2-7, respectively, when 750 I.U. HCG was injected at the 
first signs of estrus. Scanlon et al. (1968) demonstrated that when 
cows were given 3000 I.U. PMSG on day 16 of the cycle, followed by 2000 
I.U. HCG at the fime of mating, the number of ovulations per cow ranged 
from 1 to 55. The number of ovulations as a percent of the total folli-
cular response increased from 12.9% to 85.3% as the days from PMSG to 
estrus increased from 1 to 5. 
Schilling and Holm (1963) reported that a series of two injections 
of gonadotrophin, one early and the other late in the cycle, would tend 
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to reduce the number of ovulations. They hypothesized that a follicle 
begins to develop during or just after estrus, and that this follicle 
grows with others which become atretic. They theorized that an addi-
tional dose of PMSG during the early stage of the cycle would either 
prevent this process of atresia or stimulate the growth of new follicles. 
They felt that this injection would then produce more follicles ready 
to develop and that the second injection of PMSG would cause these fol-
licles to grow, instead of many new ones. However, today it is known 
that only the largest follicle present during the three days before 
estrus will ovulate. 
Hafez et al. (1964) followed this pattern by administering 750 I.U. 
PMSG on day 5 plus either 1500 I.U. or 2000 I.U. PMSG on day 16 of the 
estrous cycle. They found that these treatments produced ovulations 
which ranged from 1-12 and 2-8 for the two groups, respectively. 
Laster et al. (1971) obtained a range of 3-6 ovulations per cow 
when treated with 1500 I.U. PMSG on day 5 and 2000 I.U. PMSG on_ day 17 
of the estrous cycle, followed by 2500 I.U. HCG at the day of estrus. 
Fifty percent of the cows so treated had 3 ovulations. However, when 
either 2500 I.U. HCG or 4000 I.U. HCG was administered three days after 
PMSG, regardless of when estrus occurred, 73.7% of the cows had either 
two or three ovulations. 
Hallford (1975) compared treatments involving either a single in-
jection of 2000 I.U. PMSG on day 17 of the estrous cycle or injections 
of 1500 I.U. PMSG on day 5 and 2000 I.U. PMSG on day 17 of the estrous 
cycle. Cows given a single injection had an average ovulation rate of 
2.8 as compared to 1.5 for the cows which received two injections. 
However, 50% of the single injection cows had between two and four 
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ovulations while only 13.3% of the other cows were within this range of 
ovulations. When heifers were given a single injection of PMSG, there 
was an average of 3.1 ovulations with 36.4% of the heifers having 
between two and four ovulations. With a series of two PMSG injections 
in heifers, the average ovulation rate was 1.8 and 50% having two to 
four ovulations. For some unknown reason, heifers and cows responded 
differently to a single vs. two PMSG injections. 
In contrast, Schwartz et al. (1969) showed that a series of two 
injections in heifers produced more ovulations than a single injection. 
He observed an average of 6.56 ovulations per heifer with a range of 
0-16 in a group which received 1500 I.U. PMSG on day 5 and 2000 I.U. 
PMSG on day 15 of the estrous cycle, followed by an injection of 1000 
I.U. HCG at estrus or day 21. However, in the group of heifers which 
received 1500 I.U. PMSG on day 15, followed by 1000 I.U. HCG at estrus 
or day 21, there was an average ovulation rate of 4.72 and a range of 
0-13 ovulations. Therefore, although a series of two gonadotrophin 
injections may tend to reduce the average number of ovulations, it does 
not appear to be a method for accurate control of ovulation rate. 
Effect of PMSG on Ovarian Hormones 
The development of methods for quantifying hormone concentrations. 
in the blood has offered a means for studying the mechanism of action 
of exogenous gonadotrophins. When this mechanism is known, it may be 
possible to better control the superovulatory response. 
PMSG has a dramatic effect on circulating concentrations of pro-
gesterone and estradiol. Spillman et al. (1973) reported that when 
prepuberal heifers 2-5 months old were given 1250-2000 I.U. PMSG 
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followed in 5 days by 75 mg LH, their plasma progesterone increased from 
less than 0.5 ng/ml to greater than 100 ng/ml within 10 days after the 
LH injections. However, none of the follicles ovulated spontaneously, 
indicating that some of the hormonal relationships between the ovary and 
the pituitary gland are not well established in the prepuberal animal. 
When post puberal heifers were injected with 3000 I.U. PMSG on day 15 
or 16 of the estrous cycle, followed by 2500 I.U. HCG four days later, 
the progesterone concentration increased to over 60 ng/ml, which is 
higher than the 10 ng/ml maximum during the normal estrous cycle. 
Hendricks et al. (1973) treated three groups of animals with either 
0, 1600 or 3200 I.U. PMSG on day 16 of the estrous cycle. Be reported 
that the mean plasma progesterone concentration began to decrease sig-
nificantly 60 hours before estrus for the cows given 0 or 1600 I.U. 
PMSG and about 36 hours before estrus for the cows given 3200 I.U. 
PMSG. The progesterone concentration decreased to less than 1 ng/ml 
by 24 hours before estrus in the control cows compared to 12 hours and 
6 hours before estrus for the cows given 1600 I.U. and 3200 I.U., respec-
tively. The mean rates of regression of the corpora lutea were signifi-
cantly steepr for the 3200 I.U. group than for either of the other two 
groups. This indicated that the plasma progesterone concentration 
remained higher for a longer period in the cows given 3200 I.U. PMSG, 
and then decreased at a greater rate once the concentration began to 
decline. 
Hendricks et al. (1973) also studied the plasma concentration of 
estradiol after PMSG. He reported that the mean rates of increase in 
estradiol concentration were 0.08, 1.0 and 1.2 pg/ml/hour for the groups 
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which received o, 1600 and 3200 I.U. PMSG, respectively, when estradiol 
was measured over the four day period prior to estrus. 
Hallford (1975) injected one group of cows with 2000 I.U. PMSG on 
day 17 of the estrous cycle and another group with 1500 I.U. PMSG on 
day 5 and 2000 I.U. PMSG on day 17. Plasma progesterone increased and 
remained between 12 and 16 ng/ml from days 9 to 19 of the cycle for the 
group which received two injections as compared to values between 6 and 
9 ng/ml for the same time period in the cows given PMSG on day 17. 
When this is compared to a maximum of about 10 ng/ml during the normal 
estrous cycle, it is evident that an early injection of PMSG in luteo-
trophic in cows. 
Hallford (1975) also reported that plasma estradiol increased from 
2 pg/ml to greater than 10 pg/ml after the injection of PMSG on day 5 
and decreased to less than 4 pg/ml by day 15 of the cycle. Estradiol 
increased again after the second PMSG injection on day 17 to a maximum 
of about 14 pg/ml. When PMSG was only given at day 17, plasma estradiol 
remained low (2-3 pg/ml) and increased at the time of PMSG injection 
(day 17) to a maximum of approximately 18 pg/ml. These values are much 
greater than the maximum concentrations of 6-9 pg/ml during a normal 
estrous cycle, indicating that PMSG has a dramatic effect on plasma 
estradiol as well as plasma progesterone. 
Response to Repeated Injections of PMSG 
Another problem associated with the use of PMSG is the possibility 
that cows will develop a refractoriness to repeated PMSG injections. A 
decrease in the response to the gonadotrophin has been reported from 
several studies in which cows were injected with PMSG on successive 
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estrous cycles. In 1953 Willet and Buckner reported that by using vari-
ous concentrations of FSH and PMSG, they obtained an average of 12.9 
ovulations per animal after the first injection. This decreased to 3.1 
ovulations after the fourth successive injection when the injections 
ranged from 18 to 218 days apart. 
Jainudeen et al. (1966) found no difference in the superovulatory 
response when they initially injected nine cows with either 1500 I.U. 
or 2000 I.U. PMSG followed by 3000 I.U. PMSG 7 months later. However, 
they observed that when cows were treated with 3000 I.U. PMSG during 
four successive estrous cycles, the ovaries ceased being stimulated. 
In addition, they reported that the antigonadotrophin in the serum of 
the treated cows was low prior to the second injection and increased 
to a maximum 16 days after the fourth PMSG injection. 
On the basis of results obtained in a series of experiments, Cole 
et al. (1957) concluded that antihormone formation was not a serious 
factor in the clinical use of PMSG if minimal physiological doses were 
used. No studies have been concerned with the effect of doses of PMSG 
repeated only at yearly intervals, as in the production of multiple 
births. 
Prostaglandins 
Prostaglandins were first reported about forty-five years ago, but 
they received very little attention until the 1960's. Since that time 
they have been studied quite extensively and their physiological actions 
have been shown to be very diverse and to affect many tissues. 
In 1930 Kurkrok and Lieb found that human seminal plasma caused 
contraction of uterine tissue. Goldblatt (1935) and von Euler (1935) 
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reported that the contractile effect of either human or ram semen on 
uterine tissue could not be accounted for by any of the known compounds 
in semen. They hypothesized that this compound came from the prostate 
gland and gave it the name prostaglandins. 
It wasn't until about thirty years later that Berstrom and his col-
leagues reported the structure of prostaglandins (Berstrom et al., 1969). 
They found that the compounds were highly active, lipid soluble, unsatu-
rated hydroxy acids, all of which contain 20 carbon atoms and had the 
same basic carbon skeleton, prostanoic acid. The primary prostaglandins 
are E1 , E2 , E3 , Fla' F2a' and F3a. The E type prostaglandins all contain 
lla-hydroxy and 9-keto groups on a five membered ring. The F type pro-
staglandins are similar to the E compounds except the 9-keto group is 
reduced to a hydroxyl group. All of the primary prostaglandins contain 
at least one double bond in their side chains. E1 and F1 contain only 
one double bond. E2 and F2 have two double bonds and E3 and F3 contain 
three double bonds. The F prostaglandins can also be either a or B 
depending on which of the two isomeric alcohols it resembers. The a 
isomers are the only ones which occur naturally. Therefore, the com-
pounds are named according to their structure, E or F, with a subscript 
indicating the number of double bonds. Gnerally, the term prostaglandin 
is reduced to PG and is followed by the letter, subscript number and a 
or B for any particular isomer, i.e. PGF2a. 
By 1969, Berstrom et al. had isolated 14 different naturally occur-
ring prostaglandins from almost every tissue in the body and they hypo-
thesized that these compounds were ubiquitous among mammalian tissue. 
In 1969, Pharriss and Wyngarden demonstrated that PGF2a caused a 
rapid decrease in the progesterone content of ovaries from pseudopregnant 
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rats. Mccraken et al. (1972) performed a series of intricate experiments 
involving autotransplantation of the ovaries to the neck of sheep. When 
an ovary with a functional corpus luteum was transplanted to the neck, 
the corpus luteum did not regress. However, when both the ovary and the 
uterus were transferred to the neck, the corpus luteum regressed in the 
normal length of time. This suggested that a factor from the uterus was 
required to cause luteal regression. They then transplanted an ovary 
with a corpus luteum to the neck and infused PGF2a into the ovary's 
blood supply and noted a rapid regression of the corpus luteum. This 
demonstrated that in sheep, PFG2 was luteolytic, working directly on a 
the ovary and not through the uterus. 
Barrett et al. (1971) and Thornburn and Nicol (1971) conducted 
similar studies which supported McCracken's work. Bland et al. (1971) 
found that the concentration of PGF2a increased in the uterine vein of 
sheep on days 14, 15 and 16 of the estrous cycle, but it was not detect-
able at any other stage. This is direct evidence that PGF2a is the 
luteolytic factor produced by the uterus of the sheep. 
Prostaglandins are now being studied as a potential method for 
controlling the estrous cycle of cattle. Liehr et al. (1972) observed 
that injection of 500 ug PGF2a into the ipsilateral horn of the uterus 
in heifers every hour for six hours did not affect cycle length when 
administered on day 5 of the estrous cycle. However, when 6 mg PGF2a 
was injected into the ipsilateral horn on day 9 of the estrous cycle, 
the animals returned to estrus 2.4 days later and plasma progesterone 
concentrations decreased to undetectable concentrations within two days 
after the treatment. 
15 
In a similar study, Louis et al. (1972) deposited 5 mg PGF2a in the 
ipsilateral uterine horn of the uterus of cows on day 11 of the estrous 
cycle and caused luteal diameter to decrease from 2.7 cm to 0.4 cm by 
48 hours later. Estrus occurred an average of 68 hours after treatment 
with ovulation occurring an average of 94 hours after treatement. Simi-
lar results were reported by Rowson et al. (1972). They found that 
PGF2a depositied in the uterus of cows prior to day 5 of the estrous 
cycle had no effect on estrous cycle length. 
Prostaglandin has also been shown to be effective when administered 
as a systemic injection. Louis et al. (1973) reported that 30 mg PGF2a 
in 1.5 ml saline injected IM into heifers during diestrus (8-18 days 
after estrus) caused plasma progesterone concentrations to decrease from 
4.0 ng/ml at the time of treatment to 1.2 ng/ml 72 hours later. Estrus 
occurred an average of 74 hours after treatment and ovulation occurred 
an average of 104 hours after treatment. However this study also demon-
strated that when PGF2a was administered to heifers during mestestrus 
(3 days after estrus) normal corpus luteum growth was not affected. In 
a similar study, Nancarrow et al. (1974) injected cows with either 25 
mg or 30 mg PGF2a and normal luteal regression was induced. 
These studies established that prostaglandins, specifically PGF2a, 
when administered to a cow with a functional corpus luteurn, would cause 
rapid regression of the corpus luteum, drastically reducing plasma 
progesterone levels and be followed by the .occurrence of estrus about 
three days later. Therefore, PGF2a' could be used to synchronize the 
estrous cycles of groups of cows. 
The fertility of cows at the first estrus after treatment with 
PGF2a was determined by Lauderdale et al. (1974) with an extensive 
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experiment at four geographic locations using 392 cattle. The results 
of their study demonstrated that normal fertility occurred at the syn-
chronized estrus and timed inseminations without estrus detection were 
possible. Similarly, Hafs et al. (1974) found that fertility in cows 
treated with PGF2a was not different from that of control cows. 
Rowson et al. (1972) reported that when a single systerr.ic injection 
of PGF2a was administered to cows one day after PMSG, the eggs produced 
were normal and resulted in normal fertility when transferred to cows 
which had been synchronized with PGF2a. Therefore, because PGF2a has 
been shown to be luteolytic in cows, and also has no adverse effect on 
fertility, it may be possible to use this compound with PMSG to reduce 
the time interval from PMSG treatment to estrus, thereby reducing the 
number of ovulations. 
CHAPTER III 
MATERIALS AND METHODS 
General 
This study was conducted from May 1975 through July 1975. It in-
volved fifty Angus cows and. heifers maintained under range conditions 
on native pasture at the Southwest Livestock and Forage Research Center, 
El Reno, Oklahoma. The hormone analysis was conducted at the Animal 
Science Physiology Laboratory on the campus of Oklahoma State University, 
Stillwater, Oklahoma. 
Pregnant Mare Serum Gonadotrophin 
The pregnant mare serum gonadotrophin (PMSG) used in this study had 
been obtained in bulk from Argentina and was stored at -10°C. When orig-
inally received it had been standardized to a potency of 200 I.U. per 
mg. This potency was confirmed just prior to use by the rat bioassay 
described by Cole and Erway (1941). The test animals used were twenty-
one day old immature female albino rats of the Texas Inbred Mice Company, 
strain Tex:SDD. The standard PMSG was the World Health Organization 
2nd International Standard for Serum Gonadotrophin, Equine for Bioassay, 
provided by the Hampsted Laboratories, London. 
The bioassay was conducted with a 3~3 factorial arrangement of 
treatments with three sources of PMSG (the International Standard plus 
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PMSG from two separate containers, A&B, sotred in the Animal Science 
Physiology Lab.) and three dose levels (6, 9 and 13 I.U.) of each source 
of PMSG. The PMSG was dissolved in sterile saline solution and injected 
subcutaneously into groups of five rats per PMSG level. The rats were 
sacrificed 48 hours post injection and the ovaries were removed and 
weighed. Mean ovarian weights for the five rats in each of the levels 
tested are in Table I. An analysis of variance (Snedecor and Cochran, 
1967) showed no evidence to suggest that either source of PMSG was dif-
ference than the International Standard (P~ .25) and the potency was 
assumed to be 200 I.U. per mg. 
Just prior to the bioassay, the PMSG was dissolved in saline solu-
tion so that 1 ml of the solution contained 1000 I.U. It was then 
divided into vials containing 2000 I.U. per vial and frozen and stored 
at -10°C at the Physi"ology Lab in El Reno. Just prior to injection the 
required amount of PMSG was thawed and mixed to a volume of approxi-
mately 5 ml per injection. Injections were given subcutaneously in the 
shoulder region of the animal. 
Prostaglandins 
The prostaglandin F2a-Tham salt used in this study was provided by 
the Upjohn Company. Prior to the start of the study the prostaglandin 
was diluted in sterile H2o at a concentration of 33.5 mg/5 ml which pro-
vided a dose level of 25 mg prostaglandin F2a' frozen and stored at -l0°C 
until used. The prostaglandin injections were given intramuscularly in 
the rump of the animal. 
Source 
Standard 
PMSG A 
PMSG B 
* Mean ± 
TABLE I 
MEAN OVARIAN WEIGHTS 
FOR PMSG BIOASSAY 
Dose 
6 I. u. 9 I. u. 
* 21. 67±1. 66 33.80±3.17 
26.82±1.32 29. 76±1. 75 
32.48±5.62 33.96±1.63 
standard error. 
Design 
19 
13 I.U. 
39.50±8.27 
38.78±3.58 
48.30±6.96 
Thirty-four Angus cows and sixteen yearling heifers were used in 
this study. The animals were observed twice daily for signs of estrus. 
Estrus detection was facilitated by the use of sterile bulls equipped 
with chin ball markers. After at least one normal estrous cycle, the 
animals were randomly assigned within age groups to one of five treat-
ments as described in Table II. All animals, regardless of treatment, 
were injected intramuscularly with 33.5 mg PGF2.a Tham salt between days 
7-14 of the estrous cycle. This injection was designated PGF-I. All 
subsequent prostaglandin treatments were designated PGF-II. Animals on 
all treatments were bred by natural service at the second estrus after 
PGF-I. 
Treatment I served as the control group. After the PGF-I injection 
no further treatment was applied. Treatment II received 2000 I.U. PMSG 
Treatment 
I 
II 
III 
IV 
v 
TABLE II 
EXPERIMENTAL DESIGN 
Time of Injection-
Days After PGF-I 
2000 I.U. PMSG 33.5 mg PGF2aTham Salt 
12 
20 
20 
13 
13 
21 
subcutaneously on the twelfth day after PGF-I (approximately day 9 of 
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the estrous cycle) followed on the next day by an intramuscular injec-
tion of 33.5 mg PGF2aTham salt. Treatment III did not receive PMSG but 
was injected with 33.5 mg PGF2aTham salt thirteen days after PGF-I 
(approximately day 10 of the estrous cycle). 
Treatment IV received 2000 I.U. PMSG twenty days after PGF-I 
(approximately day 17 of the estrous cycle). Treatment V also received 
PMSG on day 20 post PGF-I followed by 33.5 mg PGF2aTham salt the follow-
ing day (approximately day 18 of the estrous cycle). 
Twenty ml blood samples were collected by tail vein puncture into 
20 ml evacuated glass containers. Nineteen mg of oxalic acid in 0.3 ml 
water was added to prevent clotting. The blood was transferred to plas-
tic centrifuge tubes and centrifuged at 2500 RPM for 15 minutes~ The 
plasma was then decanted into plastic vials and stored at -10°C until 
estradiol and progesterone were qunntified. 
The blood sampling schedule is presented in Table III. Blood sam-
ples were collected from all animals on the day of PGF-I and three days 
TABLE III 
BLOOD SAMPLING SCHEDULE 
Day 
7-14 
of Days Post PGF-I 
---- ~-- ------ - -- - ----
Treatment Cycle 3 12 13 14 15 16 17 18 19 20 21 22 23 24 
PGF-I bleed daily 
I 
* 
until estrus 
B B B B B B B B or day 27 
PGF-I PMSG PGF 
II 
B B B B B B bleed daily until estrus or day 21 
PGF-I PGF 
III 
B B B B B B bleed daily until estrus or day 21 
PGF-I PMSG 
IV bleed daily until 
B B B B B B B B estrus or day 27 
PGF-I PMSG PGF 
v bleed daily until 
B B B B B B B B estrus or day 27 
* B designates days blood samples were taken. 
N 
I-' 
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later. In addition, blood samples were taken from treatment I animals 
every other day during days 12-22 after PGF-I, then daily until estrus 
or day 27 post PGF-I. Animals on treatments II and III were bled daily 
until estrus or day 20 starting at day 12 after PGF-I. Animals on treat-
ments IV and V were bled every other day from day 12-20 post PGF-I and 
then daily until estrus or until day 27 (approximately day 24 of the 
estrous cycle). 
Determination of Ovarian Response 
Ovulation rates for treatments II, IV, and V were determined by 
means of a high lumbar laparotomy between days 7 and 14 days after 
breeding. Ovulation rates for treatments I and II were determined by 
rectal palpation. 
Animals were held off feed and water overnight before laparotomy. 
The hair was clipped on the animal's left side between the last rib and 
the external angle of the ileum, the area cleaned with Roccal-D and 
thoroughly rinsed with isopropyl alcohol. A total of approximately 
20 ml of a two percent procaine solution was injected along both sides 
of the incision line. An incision of approximately eight inches was 
made through the skin and outer muscle layer. The inner muscle layer 
was separated by blunt dissection and a small incision was made into 
the peritoneum to allow the hand and forearm to enter the body cavity. 
The ovaries were located and observed through a laporascope (Jacobs-
Palmer Operating Peritonescope, Richard Wolf Medical Instrument Corp., 
7046 Lyndon Ave., Rosemont, Ill. 60018). The peritoneum and individual 
muscle layers were sutured separately by means of a continuous stitch. 
The skin was sutured with umbilical tape. The surgical area was then. 
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painted with iodine and each animal received an injection of 10 ml 
Combiotic. Skin sutures were removed 10 days to two weeks later. After 
surgery the animals were returned to pasture equipped with KaMar heat 
detection patches, where they were exposed to fertile bulls equiped with 
chin ball markers to aid in determining breeding dates. 
Radioimmunoassays 
Progesterone 
Plasma progesterone was quantified by radioimmunoassay similar to 
the method of Kittock et al. (1973) as modified by Hallford (1975). 
One further modification was the elimination of the 5% trimethyl chloro-
saline in toluene rinse of the glassware because this did not affect the 
results of the assay. Standard progesterone was dissolved in freshly 
distilled ethanol so that 0.1 ml contained 0, 0.05, 0.1, 0.2, 0.3, 0.4, 
0.6 and 0.8 ng of progesterone. The antibody used was Antiprogesterone 
#869, generously supplied by Dr. G. D. Niswender, Colorado State Univer-
sity. 
Within the assay, samples of water, steer plasma and steer plasma 
plus 5 ng progesterone were quantified to determine the precision of the 
assay. When water was used in the assay its average value was 0.1±0.0 
ng/ml (mean± S.E.) (n = 15). The average value for steer plasma was 
0.4±0.1 ng/ml (n = 14) and the average value for the steer plus 5 ng 
progesterone plasma was 5.4±0.l ng/ml (n = 27), with a between assay co-
efficient of variation of 13.4%. 
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Estradiol 
Estradiol 17S was quantified by a procedure similar to that des-
cribed by Wettemann et al. (1972) as modified by Hafs et al. (1974) and 
Hallford (1975), with one modification. Following the addition of the 
antibody (Antiestradiol #244) and the estradiol competitor (3H-2,4,6,7 -
estradiol) the assay tubes were incubated at 4°C for 4 hours, rather 
than the 3 to 20 hours as described by Hallford (1975). 
Within the assay, samples of water, steer plasma, steer plasma plus 
4 pg/ml estradiol, stripped steer plasma, stripped steer plasma plus 
5 pg/ml estradiol and stripped steer plasma plus 10 pg/ml were assayed 
to determine the precision and repeatability of the assay. The stripped 
steer, plasma was produced by adding 5 mg charcoal per ml of steer plasma 
and stirring for 5 minutes, followed by centrifugation for·20 minutes 
at 6000 PRM. The above procedure was repeated a second time and the 
resulting plasma was stored at -lO~C until assayed. The average values 
for the various samples used in this assey were: water, 0.4±0.1 pg/ml 
estradiol (mean± S.E.)(n = 31); steer plasma, 4.7±0.3 pg/ml estradiol 
(n = 15); steer plus 4 pg/ml estradiol, 9.2±1.0 pg/ml (n 10); stripped 
steer plasma, 2.2±0.5 pg/ml (n = 6); stripped steer plus 5 pg/ml estra-
diol, 7.0±0.5 pg/ml (n ~ 7, c.v. = 18.2%); stripped steer plasma plus 
10 pg/ml, 11.1±0.9 pg/ml (n = 5, c.v. = 17.8%). The steer and steer 
plus 4 pg/ml samples were used during the early part of the study and 
the stripped steer samples were used during the later part of the study. 
During the course of this study, an attempt was made to use a 
second antibody to separate bound and free estradiol in the assay instead 
of charcoal and dextran. It was hoped that the double antibody assay 
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would be more sensitive than the charcoal-dextran assay that was being 
used. 
The first step in developing a double antibody assay was to obtain 
Rabbit Anti Sheep IgG (Miles-Yeda, Ltd., Lot Rl67, Code 65-130) to bind 
and precipitate the Sheep Antiestradiol IgG. This Rabbit Anti Sheep IgG 
was diluted in Phosphate Buffered Saline plus 0.1% Gelatin (PBS + Gel) 
and was used at various dilutions to precipitate the Sheep Antiestradiol 
IgG (diluted with PBS + Gel in 1:100 Normal Rabbit Serum, NRS) and with 
various concentrations of 3H-2,4,6,7 estradiol competitor. Once the 
optimum combinations of diluations had been obtained, several standard 
curves were assayed to determine the sensitivity in the assay. 
Standard estradiol concentrations of O, 1, 2, 4, 6, 10, 20, 40, 60 
and 100 pg in 0.1 ml distilled ethanol were added to assay tubes and 
dried on a heating block under N2 • Next, 200 ul Antiestradiol #244, at 
a dilution of 1:100,000 in 1:100 NRS, was added to each tube, vortexed 
gently and allowed to stand at room temperature. After 2 hours, 200 ul 
of 3H estradiol competitor containing approximately 500 cpm was added 
to each tube, vortexed gently and stored in a refrigerator at 4°C for 
24 hours; The assay tubes were then removed from the refrigerator and 
placed in an ice water bath. Then, 400 ul -of a 1:90 dilution of Rabbit 
Anti Sheep IgG was added to each tube, vortexed gently and stored at 
4°C for 48 hours. At the end of 48 hours the assay tubes were centri-
fuged at 3000 RPM for 30 minutes and a 0.5 ml sample was taken from each 
tube and counted to determine the radioactivity. Two picograms of estra-
diol was easily distinguished from no hormone with 95% confidence (n=8). 
Therefore, allowing for procedural losses and for an aliquot to determine 
recovery, the sensitivity of the assay was about 2.4 pg/ml serum. 
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Figure 1 depicts standard curves from both the double antibody 
assay and the charcoal-dextran assay. It had been hoped that the double 
antibody assay would increase the sensitivity and repeatability of the 
standard curve in the region .from 1 pg/ml to 6 pg/ml. However, the 
6 pg/ml standard displaced only 10% of the 3H estradiol as compared to 
the zero tube for the double antibody assay._ This was not as sensitive 
-
as the charcoal-dextran assay already in use, in which the 6 ph/ml 
standard displaced 15-20% of the 3H estradiol as compared to the zero 
tube. Therefore, the double antibody assay was not used in this study. 
Statistical Analysis 
Ovulation rates were analyzed by analysis of variance using a com-
pletely randomized design (Snedecor and Cochran, 1967). The time from 
treatment to estrus and endocrine data were analyzed by using the Stu~ 
dentls t test (Steel and Torrie, 1960). Simple correlations were used 
to describe the relationship between maximum plasma estradiol concentra-
tions and ovulation rate. 
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CHAPTER IV 
RESULTS AND DISCUSSION 
Reproductive Response 
Originally 10 animals were assigned to each treatment on the basis 
of an observed estrus. However, if the animals were obviously not in 
the luteal phase of the estrous cycle at the time of PGF~I, or did not 
respond to the prostaglandin treatment, they were eliminated from the 
study. The criteria for an animal to be eliminated were if it did not 
have a normal plasma progesterone concentration at the time of PGF-I 
injection and/or if plasma progesterone did not decrease to 1 ng/ml by 
three days after PGF-I. Consequently, the data on only 7 animals in 
treatments I and II, 9 animals in treatment III, 8 animals in treatment 
IV and 10 animals in treatment V were used. 
Occurence of Estrus After Treatment 
Occurence of estrus after treatment is depicted in Table IV. 
Thirty-six of the 41 animals (87.8%) in this study exhibited estrus 
following PGF-I. The duration to estrus after PGF-I averaged 3.36±0.21 
days for all animals. These results are similar to those reported by 
Lauderdale et al. (1974) and Nancarrow et al. (1974). 
The control animals had an average cycle length of 22.50±0.81 days 
from the first to the second estrus after PGF-I, with six of seven ani-
mals exhibiting a second estrus. 
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Item I 
Number 7 
Estrus Post 
PGF-I 
Number 7 
Days 3. 6±0. 4 
TABLE IV 
DAYS TO ESTRUS AFTER 
TREATMENT 
Treatment 
II III 
7 9 
5 8 
3. 8±1. 0 3.0±0.2 
Estrus After 
Treatment 
Number 6 1 5 2 8 2 
Days 22.5±0.8 3. 0±0. 4 3.5±0.3 
1 Days from 1st and 2nd estrus after PGF-I. 
2 Days from PGF-II to estrus. 
3 Days from PMSG to estrus. 
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IV v 
8 10 
6 10 
3.3±0.6 3.2±0.2 
7 3 
4.3±0.6 
10 3 
3.8±0.2 
Treatment II animals, which received 2000 I.U. PMSG on day 12 post 
PGF-I (day 10 of the estrous cycle) and 33.5 mg PGF2aTham salt on day 
13 post PGF-I, had an average interval to estrus following PGF-II of 
3.0±0.4 days, and 5 to 7 animals exhibited estrus. Treatment III ani-
mals, which were given only prostaglandin during mid cycle, had a sim-
ilar time to estrus of 3.5±0.3 (P > .30) and 8 of 9 animals exhibited 
estrus. These results suggest that PMSG given in mid cycle and followed 
one day later by PGF2a, does not lengthen the time to estrus when com-
pared to an injection of prostaglandin only. 
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Treatment IV animals which received 2000 I.U. PMSG on day 20 post 
PGF-I (approximately day 17 of the estrous cycle), were in estrus an 
average of 4.3±0.6 days after PMSG with 7 of 8 animals exhibiting an 
estrus. This period from treatment to estrus is similar to the results 
reported by Hallford (1975). He observed a period of 4.9±0.7 days from 
treatment to estrus for cows and 4.6±1.l days for heifers when 2000 I.U. 
PMSG was administered on day 17 of the estrous cycle. Similarly, treat-
ment V animals, which received the same dose of PMSG on day 20 and 33.5 
mg PGF2a on day 21 post PGF-I, were in estrus 3.8±0.2 days (P > .30) 
after PMSG and all 10 animals exhibiting estrus. 
Ovulation and Conception Rates 
Ovulation and conception rates are presented in Table V. Ovulation 
rates for treatments II, IV, and V were similar (P > .50), being 
3.42±1.70, 4.25±1.73 and 3.40±0.91, respectively. The range in the num-
ber of ovulations was similar for all groups being 0-13 for treatment II, 
0-15 for treatment IV and 0-9 for treatment V. 
Table V also presents the percentage of each treatment group which 
were in each of three ovulation ranges. Brock and Rowson (1952) and 
Scanlon et al. (1968) reported a decrease in superovulation when the 
time from treatment to estrus was reduced. It had been hoped that the 
injection of PGF2a after PMSG would reduce the range in ovulations by 
reducing the time to estrus so that more animals would have ovulated 
2-4 eggs. However, in our study time to estrus was not reduced when 
PMSG was followed by prostaglandin. Ther~fore, these figures indicate 
that the range in ovulations was not reduced to the desirable level. 
Considering the fact that there were only ten animals on treatment V, 
I 
Item Control 
Number in Estrus 6 
Ovulation Rate 
Mean 1. 0 
Range ---
Conceived to 
Treatment Estrus 5 
Open Cows 0 
Ovulations (%) 
0-1 ---
2-4 ---
>4 ---
TABLE V 
OVULATION AND CONCEPTION RATES 
Treatment 
II III 
PMSG-Day 12 
PGF-Day 13 PGF-Day 13 
5 8 
3.42±0.17 1.0 
0-13 
3 5 
3 2 
50 ---
33 ---
17 ---
IV 
PMSG-Day 20 
7 
4.25±1. 73 
0-15 
3 
4 
38 
25 
38 
v 
PMSG-Day 20 
PGF-Day 21 
10 
3.40±0.91 
0-9 
3 
7 
30 
40 
30 
w 
I-' 
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and fewer on treatments II and IV, each range in the table contains only 
2-4 animals. In order to draw definite conculsions about the effective-
ness of PGF2a in controlling ovulation rate after PMSG, more animals 
must be used. 
Pregnancy was disgnosed by rectal polpation 60-90 days after breed-
ing. As can be seen in Table V, conception at first estrus after treat-
ment was quite low. Conception in the four treatment groups averaged 
41% as compared to 71% in the control group. Some of the reduction in 
fertility may be attributed to the laparotomies or rectal polpation, as 
suggested by Gordon et al. (1962) and Schwartz and Shelly (1969). Heat 
stress may have been responsible for the reduced fertility. Many of 
these cows and heifers were bred during July when ambient temperature 
was elevated. Another possible reason for this reduced f~rtility could 
be that only about a 30 day breeding season was p~rmitted after PMSG 
and cows may not have returned to normal ovarian function by that time. 
However, it should be noted that 4 animals in treatment IV and 7 animals 
in treatment V did not conceive to the treatment estrus and did not con-
ceive through the remainder of the 45 day breeding season. In all, 16 
of the 34 animals in the four treatment groups (47%) did not conceive 
during the entire breeding season. Three sets of multiples were born 
to cows in this study and all three sets were twins. One set of twins 
was born in each of treatments II (PMSG plus PGF2a in mid cycle), IV 
(PMSG in late cycle) and V (PMSG plus PGF2a in late cycle). 
Progesterone 
Plasma progesterone, averaged over all cows in this study, decreased 
from 7.9±0.4 ng/ml on the day of PGF-I to 0.9±0.1 ng/ml three days later, 
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which was the approximate day of estrus for most animals. These plasma 
progesterone concentrations are similar to values for day of estrus re-
ported by Louis et al. (1974), Dobson et al. (1973) and Wettemann et al. 
(1972). Although these authors reported plasma progesterone concentra-
tions of about 0.5 ng/ml, it should be remembered that the average time 
to estrus after PGF-I in this study was 3.36±0.21 days. Therefore, some 
blood samples were collected before the exact day of estrus. 
Plasma progesterone had increased to 6.3±0.4 ng/ml by day 12 post 
PGF-I, which was the first sampling time in the cycle following PGF-I. 
This value is similar to the luteal phase plasma progesterone concentra-
tions reported by Wette.mann et al. (1972) and Glencross et al. (1973). 
This indicates that the corpora lutea which developed after PGF2a pro-
duced normal amounts of progesterone. 
Figure 2 depicts the plasma progesterone in treatments I, II and 
III animals which exhibited estrus following treatment in mid cycle. 
Plasma progesterone averaged 7. 7±1.8 ng/ml, 9.8±1.1 ng/ml and 7.7±0.6 
ng/ml for treatments I, II and III, respectively, on the day that PGF-I 
was given. These values are similar for all three groups (P > .30). 
By three days later, these concentrations had decreased to similar values 
of 0.8±0.0 ng/ml, 0.9±0.1 ng/ml and 0.9±0.1 ng/ml (P > .20). 
By nine days later, (day 12 post PGF-I) plasma progesterone had in-
creased to concentrations normally found during the estrus cycle. How-
ever, the animals in treatment III had a significantly higher (P % .05) 
concentration that treatment II animals on day 12 - 8.2±1.1 ng/ml vs. 
4.9±0.8 ng/ml. The only explanation which can be proposed is that this 
difference was due to chance. 
I 0-0 Control 
I 
~IOw 0--0 PMS + PG 
-
b[) 
s R1-\ i::x-A PG 
Q.) 
i: 
0 
)..< 
Q.) 
.µ 
[JJ 
Q.) 
b[) 
0 
~ 4 
C\I 
s E 2 p., 
0 
Days After First PGF2a 
Figure 2. Plasma Progesterone In Animals Exhibiting Estrus 
Following Treatment at Mid Cycle 
w 
..,.. 
35 
On day 12 post PGF-I, animals in treatment II were injected with 
2000 I.U. PMSG. On day 13 post PGF-I, plasma progesterone in treatment 
II had increased to 8.5±2.0 ng/ml which was not significantly different 
from the 10.0±1.2 ng/ml found in treatment III animals (P > .40). On 
day 13 post PGF-I both treatments II and III received 33.5 mg PGF2aTham 
salt. Plasma progesterone decreased rapidly and similarly in both 
treatments II and III to 1.9±0.3 ng/ml and 3.6±0.6 ng/ml by 24 hours 
after the PGF2a injection, and 1.0±0.1 ng/ml and 0.7±0.1 ng/ml by 72 
hours after the injection of prostaglandin for treatments II and III, 
respectively. These results are similar to those reported by Louis 
et al. (1974) and Nancarrow et al. (1974) for progesterone values 72 
hours after PGF2a injection. Control animals exhibited normal luteal 
growth during this period. The plasma progesterone concentrations in 
the control groups for days 12, 14 and 16 post PGF-I were 5.8±0.5, 
7. 4±1.1 and 8. 2±1. 3 ng/ml. 
Of the 2 cows which did not exhibit estrus in treatment II (PMSG 
plus. PGF2 in mid cycle), one had plasma progesterone concentrations 
- a 
similar to other cows on that treatment. However, the other heifer 
apparently did not respond to the PGF2a inje~tion given after PMSG. The 
plasma progesterone concentration for this animal continued to increase 
and reached a maximum of 18.24 ng/ml 7 days after the PMSG injection. 
Only one heifer on treatment III (PGF2a in mid cycle) did not ex-
hibit estrus following treatment. The plasma progesterone concentration 
in this animal was 11.4 ng/ml on day 13 post PGF-I when the second pro-
staglandin injection was administered. Progesterone decreased to 6.6 
ng/ml one day after PGF-II and to a minimum value of 3.1 ng/ml 3 days 
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after prostaglandin treatment, at which time it started increasing again. 
The reason for this response is not clear. 
These results indicate that PMSG given at mid cycle does not signif-
icantly increase plasma progesterone when prostaglandin is given the 
next day. In addition, the luteal regression after PGF2a does not appear 
to be altered when PMSG is given the previous day. 
Plasma progesterone in animals exhibiting estrus after treatment 
in late cycle is depicted in Figure 3. Progesterone was similar for 
all three treatments between days 12-20 post PGF-I increasing from 
5.8±0.5 to 8.2±1.7 ng/ml for the control; from 6.5±0.8 ngiml to 7.99±0.79 
ng/ml for treatment IV; from 6.6±0.9 ng/ml to 10.20±0.7 ng/ml for treat-
ment V. 
Following the injection of treatments IV and V with 2000 I.U. PMSG 
on day 20 post PGF-I, plasma progesterone increased 12.6±0.8 ng/ml in 
treatment IV and to 12.1±0.6 ng/ml in treatment V within one day. These 
values could not be tested against the progresterone for the control 
group because no blood sample was taken from this group on day 21 post 
PGF-I. 
Treatment V animals received 33.5 mg PGF2aTham aalt the day after 
PMSG, or approximately day 18 of the estrous cycle. Following this in-
jection plasma progesterone decreased from 12.1±0.6 ng/ml on the day of 
treatment to 2.6±0.4 ng/ml one day later. This value was significantly 
·less than the 10.8±2.3 ng/ml found in the control animals (P < .05). 
Plasma progesterone had decreased to 1.5±0.4 ng/ml by 2 days after the 
prostaglandin injection in treatment V and this was lower than the 
8.5±1.5 ng/ml in treatment IV animals (P < .01) and lower that the 
5.0±1.5 ng/ml found in the control animals (P ~ .05). By three days 
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after the prostaglandin treatment, or on approximately day 21 of the 
estrous cycle, plasma progesterone had declined to 1.2±0.5 ng/ml in 
treatment V. This was not different than the 4.9±1.9 ng/ml found in 
treatment IV (P > .10) or the 3.9±1.9 ng/ml found in the control animals 
(P > .10). Throughout this time period of days 22-24 post PGF-I, the 
plasma progesterone in treatment IV was never significantly elevated 
over the progesterone found in the control animals (P > .20). 
One cow in treatment IV did not exhibit estrus following treatment. 
Plasma progesterone in this animal increased from 12.8 ng/ml on the day 
of the PMSG injection to a maximum of 16.2 ng/ml 3 days later, which was 
approximately day 20 of the estrous cycle. Plasma progesterone began to 
decrease rapidly and was 0.8 ng/ml on day 27 post PGF-I (day 24 of the 
estrous cycle) when blood sampling was terminated. It is possible that 
if the observation continued another one or two days, this animal would 
have been detected in estrus. 
These results indicate that when PGF2 is administered one day after a . 
PMSG in late cycle, plasma progesterone is significantly reduced during 
the two days after prostaglandin compared to when PMSG is given alone. 
In addition, PMSG plus prostaglandin causes plasma progesterone to be 
significantly reduced when compared to the untreated controls over the 
two day period following the proptaglandin injection. 
PMSG plus PGF2a was administered both in mid and late cycle (treat-
ments II and V). The injection of PMSG was followed one day later by a 
plasma progesterone concentration of 8.5±2.0 ng/ml in treatment II which 
was similar to the 12.1±0.6 ng/ml for treatment V (P > .10). PGF2a was 
given to animals in each group on the day after PMSG. By one day after 
PGF2a, plasma progesterone averaged 1.9±0.3 ng/ml for treatment II and 
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2.6±0.4 ng.ml in treatment V (P > .10). This similar and rapid decline 
in plasma progesterone continued and on the third day after PGF2a' plas-
ma progesterone averaged 1.0±0.1 ng/ml in treatment II and 1.2±0.5 ng/ml 
in treatment V. This would indicate that the injection of PMSG, followed 
one day later by PGF2a, illicts a similar response in plasma proges-
terone when this treatment is given either during mid estrous cycle or 
late in the cycle. 
Estradiol 
When averaged over all animals in this study, plasma estradiol in-
creased from 3. 7±0.3 pg/ml on the day of PGF-I to 7.2±0.6 pg/ml 3 days 
later, which was the average day of estrus for most animals. These con-
centrations are similar to those reported by Wettemann et al. (1972) and 
Chenault et al. (1975). 
Plasma estradiol had decreased to 4.3±0.3 pg/ml by day 12 post 
PGF-I, which was the next sampling time in the cycle following PGF-I. 
This is slightly higher than the basal estradiol levels during the bovine 
estrous cycle reported by Wettemann et al. (1972) and Hallford (1975), 
but is similar to the basal estradiol concentrations reported by Dobson 
et al. (1974). This return to basal concentrations of plasma estradiol 
indicates that plasma estradiol levels are normal in the cycle following 
an estrus induced by PGF 2a. 
Figure 4 depicts plasma estradiol in the animals on treatments II 
and III which exhibited estrus following treatment during mid cycle. 
Estradiol concentrations for the control animals (treatment I) are in-
cluded for comparison. Control animals had an average estradiol con-
centration of 2.5±0.4 pg/ml on the day of PGF-I as compared to the 
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Figure 4. Plasma Estradiol in Animals Exhibiting Estrus Following 
Treatment At Mid Cycle 
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4.7±0.2 pg/ml found in treatment II and the 4.9±0.7 pg/ml found in treat-
ment III. This treatment I value is less than both the treatment II 
(P < .10) and treatment III (P < .05) values. This is probably due to 
an inherent difference in the basal estradiol levels between the treat-
ment groups. Despite the differences in the initial concentrations, 
plasma estradiol increased at about the same rate for the three groups 
and by three days after PGF-I had increased to 7.5±0.8 pg/ml, 7.4±0.9 
pg/ml and 9.9±2.2 pg/ml for treatments I, II and III, respectively. 
By day 12 post PGF-I, treatment II animals averaged 5.5±0.2 pg/ml 
plasma estradiol and treatment III averaged 5.3±0.7 pg/ml. These values 
were greater than the 3.2±0.5 pg/ml found in the treatment I animals on 
this same day (P < .10). This is probably related to the differences 
in basal estradiol levels which was noted on the day of PGF-I. 
On day 12 post PGF-I, animals in treatment II were injected with 
2000 I.U. PMSG. By one day later, plasma estradiol had increased to 
9.8±2.8 pg/ml. However, there was little evidence to suggest that this 
value was different than the 6.8±0.8 pg/ml found in treatment III 
(P > .20), probably as a result of the large range in estradiol levels 
found in treatment II (2.0 pg/ml - 16.0 pg/ml). 
On day 13 post PGF-I, both treatments II and III received 33.5 mg 
PGF2aTham salt (PGF-II). One day later, plasma estradiol averaged 
16.0±5.5 pg/ml for treatment II, 7.7±1.4 pg/ml for treatment III and 
3.4±0.3 pg/ml for the control animals. This value for treatment II was 
not significantly different than the treatment III value (P > .20). 
However, the treatment II value was significantly greater than the 
treatment I value (P < .05), and the treatment III value approached 
being different than that of the control (P ~ .10). 
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The rapid increase and large variation in plasma estradiol following 
PMSG and PGF2a in treatment II can probably be attributed to two causes. 
Injection of PMSG causes rapid follicular growth (Hallford, 1975; 
Schwartz and Shelly, 1969; Rowson, 1950), and accompanying this folli-
cular growth an increase in plasma estradiol can also be expected 
(McDonald, 1971). Other work has shown that PGF2a causes rapid regres-
sion of the corpus luteum and a rapid decrease in plasma progesterone. 
This was confirmed in this study, as discussed in the earlier proges-
terone section. The combination of large numbers of follicles and rapid 
follicular growth caused by the PMSG, and the rapid decline in plasma 
progesterone caused by the prostaglandin, probably account for the rapid 
increase in plasma estradiol found in treatment II. 
Although plasma estradiol in treatment III does not reach the same 
high levels found in treatment II, a rapid increase in estradiol can be 
seen after PGF-I. This is probably due to the rapid decrease in plasma 
progesterone as a result of luteal regression following PGF2a, which 
allows the follicles to grow rapidly, secreting large amounts of estra-
diol. 
By two days after PGF-II, plasma estradiol had increased to 
19.0±8.7 pg/ml in treatment II and to 9.0±1.0 pg/ml in treatment III. 
Again, there was no evidence to suggest a significant statistical dif-
ference between these two means (P > .20) due to the tremendous range 
found in treatment II (5.2 pg/ml· - 52.6 pg/ml). 
Day three post PGF-II was the average day of estrus for treatments 
II and III. The high estradiol concentration found in treatment II 
(PMSG plus PGF2a)' 17.2±2.7 pg/ml, is probably due to the large number 
of growing follicles, rapid follicular growth and the rapid progesterone 
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decline. The treatment II value is greater than the 11.7±1.1 pg/ml 
found in treatment III (P < .10) and the 3.9±0.9 pg/ml found in the 
controls (P < .01). The value for treatment III was also greater than 
the controls (P < • 01). 
This treatment III value is somewhat higher than the 6-9 pg/ml 
estradiol at estrus reported by Wettemann et al. (1972) and Chenault 
et al. (1975). These studies reported estradiol values at estrus for 
a normal cycle. The fact that the estradiol values found in treatment 
III are from an induced estrus in mid cycle may account for the elevated 
levels. Another point to consider is that the basal estradiol level in 
treatment III was significantly elevated over the control at both the 
time of PGF-I and day 12 post PGF-I. Therefore, this elevated estradiol 
at the average day of estrus might also be due to the overall higher 
estradiol concentrations found in treatment III. 
By day 4 post PGF-II, all but two animals in both treatments II and 
III had exhibited estrus. The average estradiol concentration for the 
2 animals in treatment II was 20.5±0.4 pg/ml. This value was similar 
to the 15.7±2.4 pg/ml found in the 2 animals which had not yet exhibited 
estrus in treatment III (P > .20). 
Estradiol concentrations on the actual day of estrus of each animal 
averaged 22.6±8.0 pg/ml for treatment II (PMSG plus PGF2a) and 12.4±1.4 
pg/ml for treatment III (PGF2a). However, there was no evidence to sug-
gest a significant difference between these two groups (P > .30). The 
larger estradiol concentration for the actual day of estrus in treatment 
II can probably be attributed to the large number of ovulations found 
in this group. Treatment II had an average of 3.4±0.2 ovulations per 
animal. The average plasma estradiol concentration for control animals 
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at the day of estrus was 7.0±0.6 pg/ml. Therefore, it is possible that 
animals having more than 3 ovulations could produce more than 20 pg/ml 
estradiol on the day of estrus. 
The 12.4±1.4 pg/ml estradiol found in treatment III on the day of 
estrus is higher than those values reported for estrus during the normal 
estrous cycle by Wettemann et al. (1972) and Chenault et al. (1975). 
However, this is probably due to animal variation combined with the small 
number of animals in this treatment. 
The correlation between peak estradiol values and the number of 
ovulations in treatment II was .92 (P < .05). There was one animal in 
treatment II which had plasma estradiol concentrations of 35.0 pg/ml on 
day 1 post PGF-II and 56.6 pg/ml on day 2 post PGF-II. This animal also 
had a total of 13 ovulations and this was probably the cause of such 
high estradiol concentrations. Had this animal not bee included in the 
calculations, the variation in treatment II would have been greatly re-
duced. 
There were two animals in treatment II (PMSG plus PGF2a) which did 
not exhibit an estrus following treatment. Both of these animals had 
plasma estradiol concentrations greater than 20 pg/ml from days 2-6 post 
PGF-II. One of these animals had rapidly declining plasma progesterone 
concentrations similar to the remainder of the treatment group, but the 
other had consistently high plasma progesterone from days 3-6 post 
PGF-II (6.9 ng/ml - 18.2 ng/ml). However, neither of these animals had 
multiple ovulations. Therefore, the response in these animals suggests 
that the very high levels of estradiol and/or progesterone, and the 
absence of an observed estrus cannot be attributed entirely to super-
ovulation. 
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There was one animal in treatment III (PGF2a) which did not exhibit 
an estrus following treatment. The plasma estradiol in this animal 
followed the same pattern as the remainder of the group, reaching a max-
imum of 9.9 pg/ml on day 5 post PGF-II. 
It should be noted that the control animals exhibited normal plasma 
estradiol concentrations during the sampling period, days 12, 14, 16 and 
18 post PGF-I, ranging from 3.5±0.5 pg/ml to 4.0±0.6 pg/ml. 
These results indicate that the injection of 2000 I.U. PMSG, fol-
lowed one day later by 33.5 mg PGF2aTham salt, in mid cycle causes a 
rapid increase in plasma estradiol. This treatment elevates plasma 
estradiol over those concentrations found in the control animals by the 
first day after prostaglandin treatment. There was a trend for plasma 
estradiol after PMSG plus prostagland1n in mid cycle to be greater than 
when prostaglandin is given alone in mid cycle, although this difference 
was not statistically different except for the third day after prosta-
glandin treatment. Plasma estradiol on the day of estrus for treatment 
II was not significantly different than that found in treatment III. 
The correlation coefficient between peak plasma estradiol and number of 
ovulations following PMSG and PGF2a in mid cycle was .92, indicating a 
high correlation between these two parameters. 
Plasma estradiol in animals exhibiting estrus following treatment 
in late cycle is depicted in Figure 5. The initial injection of pro-
staglandin caused plasma estradiol concentrations to increase from 
3.7±0.3 pg/ml to 7.2±0.6 pg/ml by three days later. The increase in 
plasma estradiol in treatment IV is not as great as the increase found 
in treatments I and V. However, the rapid decrease in plasma proges-
terone discussed earlier for this group is evidence of a true response 
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Treatment Late in the Cycle 
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to the prostaglandin injection. The most logical explanation for the 
day 3 post PGF-I estradiol value being low is that the maximum may have 
occurred the day before or after sampling. 
By day 12 post PGF-I, plasma estradiol had decreased to 3.1±0.5 
pg/ml for the control group, 3.9±1.0 pg/ml for treatment IV and 3.5±0.6 
pg/ml for treatment V. Plasma estradiol remained low between days 12-
20 post PGF-I for all three groups, varying between 3.2±0.5 pg/ml and 
6.2±0.9 pg/ml for treatment IV; between 3.5±0.6 pg/ml and 4.4±0.7 pg/ml 
for treatment V and between 3.1±0.5 pg/ml and 4.0±0.6 pg/ml for the 
control animals. Some of these basal estradiol levels may appear quite 
high. In some instances, as few as four values comprise a daily mean, 
because of missing samples. Glencross et al. (1973) and Lemon et al. 
(1975) have reported that some animals will exhibit a small estradiol 
peak during diestrus. In this study, several animals in treatments IV 
and V had a daily estradiol concentration of 8 pg/ml once or twice 
during diestrus. On some sampling days, more than one animal within 
a treatment group had increases in estradiol which increased the average 
estradiol concentration for that day. 
Following the injection of 2000 I.U. PMSG on day 20 post PGF-I in 
treatments IV and V, plasma estradiol had increased one day later to 
9.3±2.7 pg/ml in treatment IV and to 8.0±0.9 pg/ml in treatment V 
(P > .50). These values are similar to those reported by Hallford 
(1975) for one day after the injection of PMSG in late cycle. This 
rapid increase in plasma estradiol is probably the result of rapid 
follicular growth caused by the PMSG. 
On day 21 post PGF-I, or approximately day 17 of the estrous cycle, 
treatment V received an injection of 33.5 mg PGF2aTham salt. Plasma 
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estradiol on day 22 post PGF-I averaged 22.1±10.2 pg/ml for treatment 
IV. There was no evidence to suggest a difference between this value 
and 15.9±6.8 pg/ml for treatment V (P > .50), or the 3.9±0.4 pg/ml found 
in the control animals (P > .10). The trememdous range in estradiol 
values found in treatment IV on day 22 post PGF-I (6.0 pg/ml - 83.7 
pg/ml) produces a very large variance which accounts for the fact that 
the estradiol value for this treatment is not significantly higher than 
that for the control animals. The rapid increase in plasma estradiol 
found in treatment V is probably due to the combination of rapid folli-
cular growth caused by the PMSG, and the rapidly declining plasma pro-
gesterone following the prostaglandin injection. 
By day 23 post PGF-I, or approximately day 20 of the estrus cycle, 
plasma estradiol had increased to 32.7±9.0 pg/ml for treatment IV (PMSG 
in late cycle) which was significantly greater than the 7.9±1.2 pg/ml 
found in the control animals. The plasma estradiol concentration in 
treatment IV was not significantly different from the 17.6±5.5 pg/ml 
observed in treatment V, although there was a trend for the treatment 
IV estradiol to be greater than treatment V (P ~ .10). However, on day 
24 post PGF-I, the 8.7±2.5 pg/ml found in treatment V was significantly 
less than the 43.8±16.6 pg/ml estradiol found in treatment IV (P < .10). 
Treatment V (PMSG plus PGF2a in late cycle) exhibited rapid luteal 
regression as evidenced by plasma progesterone decline. Although the 
time to estrus was not significantly different between these two groups 
(4.3±0.6 days vs. 3.8±0.2 days for treatment V) there was a trend for 
the prostaglandin group to have a shorter time to estrus. These differ-
ences are probably due to the PGF2a given to treatment V. This shorter 
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time to estrus would allow less time for the follicles to grow, thereby 
secreting less estradiol prior to estrus. 
The 6.9±1.6 pg/ml of plasma estradiol found in the control animals 
on day 24 post PGF-I was significantly less than the 43.8±16.6 pg/ml 
found in treatment IV (P < .10). 
By day 25 post PGF-I, or approximately day 22 of the estrous cycle, 
there were only two animals which had not exhibited an estrus in treat-
ment IV. Plasma estradiol averaged 51.3±33.7 pg/ml for these animals. 
On this same day there were also two animals in treatment V which had 
not exhibited estrus and these averaged 11.0±2.4 pg/ml estradiol. Five 
of the six control animals had not exhibited estrus by day 25 post PGF-I 
and there averaged 7.2±2.4 pg/ml estradiol. 
The estradiol concentrations for the day of estrus in treatment IV 
averaged 41.2±4.8 pg/ml. This was significantly higher than the 15.7± 
5.9 pg/ml found on the day of estrus for treatment V (P < .05) and also 
higher than the 7.0±0.6 pg/ml in the control group (P < .001). 
The very high estradiol concentration on the day of estrus in treat-
ment IV can probably be attributed to two factors. This group has an 
average of 4.2±1.7 ovulations per animal. This number of growing foll-
icles, combined with the longer time that they had to grow and secrete 
estradiol prior to estrus (4.3±0.6 days) is probably the reason that 
plasma estradiol was so great. 
The estradiol concentration on the day of estrus in treatment V 
(PMSG plus PGF2a in late cycle) was also elevated above the normal 
estrus value of 6-9 pg/ml estradiol. This is probably due to the fact 
that this group had an average of 3.4±0.9 ovulations per animal. The 
reason that the estradiol concentration at estrus in treatment V is less 
than that found in treatment IV is probably that the time to estrus 
following treatment was slightly less for treatment V, allowing less 
time for follicle growth and estradiol secretion. 
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The 7.0±0.6 pg/ml for the day of estrus in the control animals 
agrees with those values reported by Wettemann et al. (1972), Chenault 
et al. (1975) and Glencross et al. (1974). Correlations between maxi-
mum estradiol concentrations and the number of ovulations were .71 
(P < .10) for treatment IV and .84 (P < .005) for treatment V. This 
would indicate that maximum plasma estradiol values following PMSG 
and/or PGF2a in late cycle is correlated to ovulation rate. 
There was one animal in treatment IV which did not exhibit estrus 
following treatment. The plasma estradiol in that animal followed the 
same pattern displayed by the others on treatment IV, reaching a maxi-
mum of 23.1 pg/ml on day 24 post PGF-I. 
There was one animal in the control groups which did not exhibit 
a second estrus after PGF-I. The plasma estradiol in this animal fol-
lowed the same pattern as the other controls reaching a maximum of 
9.~. pg/ml on day 26 post PGF-I, or approximately day 23 of the estrous 
cycle. This would indicate that these animals either exhibited an es-
trus which was not detected, or had a silent estrus. 
PMSG plus PGF2a was administered during mid estrous cycle and late 
in the cycle (treatments II and V). The injection of PMSG was followed 
one day later by a plasma estradiol concentration of 9.8±2.8 pg/ml for 
treatment II which was similar to the 8.0±0.9 pg/ml found for treatment 
V (P > .50). PGF2a was given to each of these treatments on the day 
after PMSG. By one day after PGF2a' plasma estradiol averaged 16.0±5.5 
pg/ml for treatment II and 15.9±6.8 pg/ml in treatment V (P > .50). At 
. ;_t 
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two days after PGFZa' animals on treatment II averaged 19.0±8. 7 pg/ml 
estradiol and treatment V averaged 17.6±5.5 pg/ml estradiol. This would 
indicate that estradiol response after PMSG plus PGF2a given during mid 
estrous cycle is similar to the response found after this same treatment 
in late cycle. 
These results indicate that an injection of PMSG in late cycle will 
cause plasma estradiol to be elevated over the untreated controls by 
three days after the PMSG injection. PMSG given alone in late cycle did 
not signifiantly increase plasma estradiol over PMSG plus prostaglandin 
given in late cycle until the fourth day after the PMSG treatment, al-
though a trend toward greater estradiol in treatment IV was evident by 
the third day after PMSG. One reason why differences in plasma estra-
diol between treatments IV and V were not detected earlier could be due 
to the tremendous variation in plasma estradiol after the PMSG injec-
tions. Treatment IV animals (PMSG in late cycle) had maximum plasma 
estradiol concentrations ranging from 19.8 pg/ml to 100 pg/ml while the 
treatment V animals (PMSG plus PGF2a in late cycle) had maximum estradiol 
concentrations ranging from 13.2 pg/ml to 69.0 pg/ml. Plasma estradiol 
on the day of estrus was elevated when PMSG was given along in late 
cycle, compared to either untreated controls or PMSG plus PGF2a in late 
cycle. In addition, maximum plasma estradiol and the number of ovula-
tions are correlated following treatment with PMSG and PGF2a in late 
cycle. 
CHAPTER V 
SUMMARY 
The objectives of this study were: (1) to determine the super-
ovulatory response of cows to PMSG injections timed from an estrus in-
duced by injecting PGF2a; (2) to attempt to control the number of ovu-
lations after PMSG by reducing the time from PMSG to estrus by injection 
.of PGF2a following the PMSG injection; (3) to determine the superovula-
tory response of cows to PMSG and PGF2a given in mid cycle and in late 
cycle; (4) to determine the blood plasma concentrations of progesterone 
and estradiol associated with these treatments. 
Thirty-one Angus cows and ten yearling Angus heifers were used in 
this study. After exhibiting at least one normal estrous cycle, all 
animals were given an injection of 33.5 mg PGF2aTham salt (designated 
PGF-I) between days 7-14 of the estrous cycle and assigned to one of 
five treatment groups: I. control, no further treatment after PGF-I; 
II. 2000 I.U. PMSG on day 12 post PGF-I and 33.5 mg PGF2a on day 13 post 
PGF-I; III. 33.5 mg PGF2 Th&m salt on day 13 post PGF-I; IV. 2000 I.U. a . 
PMSG on day 20 post PGF-I; V. 2000 I.U. PMSG on day 20 post PGF-I and 
33.5 mg PGF2a on day 21 post PGF-I. All animals were bred by natural 
service at the second estrus after PGF-I. Blood samples were collected 
at various intervals throughout the treatment period via tail vein 
puncture. 
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Thirty-six of the 41 animals (87.8%) exhibited estrus following 
PGF-I with an average time to estrus 3.4±0.2 days post injection. The 
control animals had an average cycle length of 22.5±0.8 days with 6 of 
7 animals exhibiting a second estrus. Treatment II animals (PMSG plus 
PGF2a in mid cycle) averaged 3.0±0.4 days from the prostaglandin treat-
ment to estrus with 5 of 7 animals exhibiting estrus. The average time 
from prostaglandin treatment to estrus in treatment III (PGF2a in mid 
cycle) was 3.5±0.3 days with 8 of 9 animals exhibiting estrus. This 
was similar to the time to estrus found in treatment II (P > .30). A 
similar time to estrus (P > .30) after the PMSG injection was also found 
between the 4.3±0.6 days for treatment IV (PMSG in late cycle) and the 
3.8±0.2 days found in treatment V (PMSG plus PGF2a in late cycle). Seven 
of the 8 animals in treatment IV exhibited estrus and all 10 animals in 
treatment V exhibited estrus. 
Ovulation rates for the animals receiving PMSG, treatments II, IV 
and V, were 3.4±1.7, 4.2±1.7, and 3.4±0.9, respectively. There was no 
difference between ovulation responses (P > .50). Conception to the 
treatment estrus for the four treatment groups averaged 41% as compared 
to the 71% found in the control group. In all, 47% of the animals in 
the four treatment groups did not conceive during the entire breeding 
season. 
After initial injection of prostaglandin plasma progesterone de-
creased from 7.9±0.4 ng/ml on the day of PGF-I to 0.9±0.1 ng/ml three 
days later. The injection of PMSG plus PGF2a in mid cycle did not in-
crease plasma progesterone over the untreated controls. The combination 
of PMSG and PGF2a in mid cycle showed the same rate of plasma proges-
terone decrease as did PGF2a alone in mid cycle. Plasma progesterone 
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decreased from 8.5±2.0 ng/ml on the day of the second prostaglandin in-
jection to 1.0±0.1 ng/ml three days later for treatment II and from 10.1± 
1.2 ng/ml to 0.7±0.1 ng/ml over the same period for treatment III. 
Following the injection of PMSG in late cycle (day 20 post PGF-I), 
plasma progesterone increased one day later from 8.0±0.8 ng/ml to 12.6± 
0.8 ng/ml in treatment IV and from 10.2±0.7 ng/ml to 12.1±0.6 ng/ml in 
treatment V. Injection of cows in treatment V with PGF2a on day 21 post 
PGF-I was followed by significantly lower (P < .OS) plasma progesterone 
within one day compared to levels in cows given PMSG along in late cycle. 
In addition, PMSG plus prostaglandin in late cycle caused plasma proges-
terone to be significantly reduced when compared to the untreated con-
trols for the two day period after the prostaglandin treatment. The 
injection of PMSG alone in late cycle tended to increase plasma proges-
terone over the untreated controls, although this difference was not 
significant at any time after treatment. 
Plasma estradiol, averaged over all cows in this study, increased 
from 3.7±0.3 pg/ml on the day of PGF-I to 7.2±0.6 pg/ml three days later. 
The injection of PMSG in mid cycle, followed one day later by PGF2a 
(treatment II), was followed by increased plasma estradiol over the un-
treated controls by the first day after the prostaglandin treatment. 
This treatment did not significantly increase plasma estradiol over those 
concentrations found when only PGF2a was given in mid cycle (treatment 
III), except for the third day after the prostaglandin treatment. How-
ever, there was a trend toward higher plasma estradiol in treatment II. 
The very large variation in the estradiol response to PMSG in treatment 
II probably resulted in there being no evidence to suggest a difference 
between plasma estradiol concentrations in treatments II and III. Plasma 
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estradiol averaged 22.6±8.0 pg/ml on the day of estrus for treatment II 
and was 12.4±1.4 pg/ml on the same day for treatment III (P > .30). The 
correlation coefficient between peak plasma estradiol and the number of 
ovulations in treatment II was .92 (P < .OS). 
The injection of PMSG in late cycle (treatment IV) significantly 
elevated plasma estradiol over the untreated controls by the third day 
after PMSG. However, PMSG alone in late cycle did not raise plasma 
estradiol over those values for PMSG plus PGF2a given in late cycle 
until the fourth day after PMSG, although there was a trend (P ~ .10) 
toward higher plasma estradiol in treatment IV by the third day after 
PMSG. The plasma estradiol for the day of estrus after treatment aver-
aged 41.2±4.8 pg/ml for treatment IV (PMSG in late cycle). This was 
significantly higher than the 1S.7±S.9 pg/ml found at estrus for treat-
ment V (P < .OS) and also higher than the 7.0±0.6 pg/ml found in the 
control group (P < .001). The correlation coefficient for peak plasma 
estradiol and ovulation number was .71 (P < .10) for treatment IV and 
.84 (P < .OOS) for treatment V. The endocrine response after treatment 
with PMSG and PGF2a at mid cycle was similar to the response found when 
this same treatment was administered in late cycle. 
The results of this study would indicate that the injection of 
gonodotrophins for the induction of multiple births can be timed from 
an induced estrus using PGF2a, thereby reducing some of the labor re-
quired for the induction of multiple births. However, the injection of 
PGF2a after PMSG does not appear to reduce the ovulation rate compared 
to when PMSG is given alone. This would indicate that multiple birth 
production will not become practical until a method is developed for 
controlling the ovulation rate. 
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APPENDIX 
TABLES 
60 
TABLE VI 
STOCK BUFFER SOLUTIONS USED IN 
IMMUNOASSAY PROCEDURES 
1. O.S Sodium Phosphate Buffer, pH 7.S 
61 
A) Weigh 69.0 g Na2P04·H2o (monobasic) and dilute to 1000 ml with 
glass distilled H20; store at S°C. 
B) Weigh 71. 0 g Na2HP04 (dibasic) and dilute to 1000 ml with glass 
distilled H20; store at S°C. 
C) To make O.S M Sodium Phosphate, mix 1 part monobasic plus 4 
parts dibasic. Adjust pH to 7.S. 
2. Stock Phosphate Buffered Saline 
A) 120 ml of O.S M Sodium Phosphate, NaH2Po4 •H20 (monobasic) 
B) 240 ml of O.S M Sodium Phosphate, NaHP04 (dibasic) 
C) 143 g Sodium Chloride, NaCl 
D) l.7S g Thimerosol (Merthiolate) 
E) Add glass distilled H20 to a final volume of 3SOO ml 
F) Check pH, adjust if necessary. 
TABLE VII 
WORKING BUFFER SOLUTIONS USED IN 
IMMUNOASSAY PROCEDURES 
1. Phosphate Buffered Saline Working Solution (PBS) 
62 
A) Dilute one part PBS Stock with four parts glass distilled water 
2. Phosphate Buffered Saline Plus 0.1% Gelatin (PBS + Gel) 
A) Weigh 1 g Knox Gelation and dilute to 1000 ml with PBS Working 
Solution. 
TABLE VIII 
LIQUID SCINTILLATION FLUIDS 
1. Steroid Counting Fluid 
A) Weigh 15 g PPO 
B) Weigh 0.15 g POPOP 
C) Combine PPO and POPOP with 3800 ml Scintillation grade Toluene 
and mix until dissolved. 
2. Protein Binding Counting Fluid 
A) Weigh 21.7 g PPO 
B) Combine PPO with 3000 ml Scintillation Grade Toluene and mix 
until dissolved. 
Day Post 
PGF-I 
0 
3 
12 
13 
14 
15 
16 
17 
18 
* 
TABLE IX 
PLASMA PROGESTERONE IN ANIMALS EXHIBITING ESTRUS 
FOLLOWING TREATMENT IN MID CYCLE 
Trt. I 
Control 
(ng/ml) 
* 7. 7±1. 8 
0. 8±0. 0 
5.8±0.5 
7. 4±1.1 
8. 2±1. 3 
8. 8±0. 9 
Trt. II 
PMSG Day 12 
PGF ·nay 13 
9. 8±1.1 
1.0±0.1 
4.9±0.8 
8. 5±2. 0 
1.9±0.3 
1.2±0.2 
1. 0±0.1 
1.3±0.2 
Mean ± S. E. 
63 
Trt. III 
PGF Day 13 
(ng/ml) 
7.8±0.6 
1.0±0.1 
8. 2±1.1 
10. 0±1.2 
3. 6± 0. 6 
1. 4±0. 3 
0. 7±0 .1 
o. 7±0.1 
0. 5±0. 0 
Day Post 
PGF-I 
0 
3 
12 
14 
16 
18 
20 
21 
22 
23 
24 
25 
26 
27 
* Mean ± S.E. 
TABLE X 
PLASMA PROGESTERONE IN ANIMALS EXHIBITING ESTRUS 
FOLLOWING TREATMENT IN LATE CYCLE 
Trt. I Trt. IV 
Control PMSG Day 20 
(ng/ml) (ng/ml) 
* 7.7±1.8 7. 7±1.1 
0.8±0.0 1.0±0.2 
5.8±0.5 6.5±0.8 
7.4±1.1 7.1±0.5 
8.2±1.3 8.5±1.0 
8.8±0.9 7.2±0.5 
8.2±1.7 8.0±0.8 
12.6±0.8 
7.5±2.0 10.8±2.3 
5.0±1.5 8.5±2.1 
3.9±2.3 4. 9±1. 9 
3.3±2.4 3.9±2.5 
1. 6±0. 8 1. 7±0. 7 
1.6±0.0 0.8±0.0 
64 
Trt. v 
PMSG Day 20 
PGF Day 21 
7. 8±1. 2 
1.0±0.2 
6.6±0.9 
7.4±0.7 
8.5±0.8 
8.4±0.5 
10.2±0.7 
12.1±0.6 
2.6±0.4 
1.5±0.4 
l. 2±0. 5 
1. 8±0. 6 
2.5±0.0 
Day Post 
PGF-I 
0 
3 
12 
13 
14 
15 
16 
17 
18 
* Mean ± S.E. 
TABLE XI 
PLASMA ESTRADIOL IN ANIMALS EXHIBITING ESTRUS 
FOLLOWING TREATMENT IN MID CYCLE 
Trt. I Trt. II 
Control PMSG Day 12 
(pg/ml)· PGF Day 13 
* 2.5±0.4 4.7±0.2 
7.5±0.8 7.4±0.9 
3.1±0. 5 5.5±0.2 
9.8±2.7 
3.4±0.3 16.0±5.5 
19.0±8.7 
3.9±0.9 17.2±2.7 
20.5±0.4 
4.0±0.6 
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Trt. III 
PGF Day 13 
(pg/ml) 
4.9±0.7 
9.9±2.2 
5. 3±0. 7 
6. 4±0. 8 
7.7±1.3 
9. 0±1. 0 
11. 7±1.1 
15.7±2.4 
8. 9±0. 0 
Day Post 
PGF-I 
0 
3 
12 
14 
16 
18 
20 
21 
22 
23 
24 
25 
26 
27 
* Mean ± S.E. 
TABLE XII 
PLASMA ESTRADIOL IN ANIMALS EXHIBITING ESTRUS 
FOLLOWING TREATMENT IN LATE CYCLE 
Trt. I Trt. IV 
Control PMSG Day 20 
(pg/ml) (pg/ml) 
* 2.5±0.4 4. 0±0. 6 
7.5±0.8 5.3±0.6 
3.1±0.5 3. 9±1. 0 
3.4±0.3 3.2±0.5 
3.9±0.9 5.8±1.1 
4.0±0.6 6.2±0.9 
3.1±0.4 5.5±0.7 
9.3±2.7 
3. 9±0. 4 22 .1±10. 2 
7. 9±1. 2 32.7±9.0 
6. 9±1. 6 43.8±16.6 
7.2±2.4 51.3±33.7 
5.9±0.2 56.4±36.5 
6.6±0.0 10.5±0.0 
66 
Trt. v 
PMSG Day 20 
PGF Day 21 
2.6±0.5 
5.7±0.4 
3. 5±0. 6 
4.0±0.1 
4. 4±0. 7 
4.4±0.6 
3.9±0.5 
8. 0±0. 9 
15. 9±6. 8 
17.6±5.5 
8.7±2.5 
11. 0±2. 4 
5.1±2.2 
11.4±0.0 
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